Madrigal pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for 
metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical 
need. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, the 
need for liver transplant and premature mortality.

A madrigal is a form of Renaissance choral music known for beautiful harmonies. Madrigal’s work focuses 
on restoring balance and harmony to the liver, an organ that performs over 500 different vital functions in 
the human body.

What began as a small team of researchers in Conshohocken, Pennsylvania, U.S., is now a fully 
integrated biopharmaceutical company with more than 500 employees in the United States and Europe. 
United by a single purpose—to lead the fight against MASH—Madrigal has built the leading clinical 
development program in this field.

Madrigal aims to support health systems and patients living with MASH through our innovations before 
the devastating complications of advanced liver disease occur. By partnering with healthcare providers 
and the patient community, we aim to educate, empower and advocate for those impacted by MASH.
 lease join our Madrigal sponsored symposium at 13:00 in Theatre A, Wednesday 22nd October, that will 
explore MASH in people living with diabetes. We will also be at Stand B30 in the exhibition area, so 
please visit us to learn more.

This newsletter article & related email content are prepared and sponsored by Madrigal Pharmaceuticals.
MED-UK--2500002                                                                     Date of reparation: October 2025